Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study
is to further monitor whether participants with severe Hemophilia A will develop inhibitors
or antibodies at the later stage when switched from their current recombinant therapy
produced from Chinese Hamster Ovary (CHO) cell line to Kogenate-FS raised in a Baby Hamster
Kidney cell line.